A Single Ascending Dose Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Single Intramuscular Injection of Quarterly Risperidone (QUAR) for Different Formulations and Dose Strengths in Participants With Schizophrenia (QUARTZ Study)
Latest Information Update: 18 Jul 2024
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Acronyms QUARTZ
- Sponsors Rovi
Most Recent Events
- 18 Mar 2024 Status changed from planning to recruiting.
- 02 Mar 2023 New trial record